(Q58179557)
Statements
Survival advantage from imatinib compared with the combination interferon-alpha plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials (English)
Lydia Roy
Joëlle Guilhot
Tillmann Krahnke
Agnès Guerci-Bresler
Steve O'Brien
Charlene So
Giorgio Massimini
François Guilhot